Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
Agile Therapeutics第四季度调整后美元（1.46美元）未达到预期（0.92美元），销售额为362万美元，低于407万美元的预期
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.92) by 58.7 percent. This is a 83.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported quarterly sales of $3.62 million which missed the analyst consensus estimate of $4.07 million by 11.18 percent. This is a 9.53 percent decrease over sales of $4.00 million the same period last year.
Agile Therapeutics（纳斯达克股票代码：AGRX）公布的季度亏损为每股1.46美元，比分析师普遍预期的0.92美元（0.92美元）低58.7％。这比去年同期每股亏损9.00美元（9.00）增长了83.78％。该公司公布的季度销售额为362万美元，比分析师普遍预期的407万美元低11.18％。这比去年同期的400万美元销售额下降了9.53％。